T he Women's Health Initiative (WHI) hormone therapy trials were designed to assess the benefits and risks of menopausal hormone therapy taken for chronic disease prevention by predominantly healthy postmenopausal women.
1-3 The double-blinded, placebo-controlled, randomized clinical trials, conducted among US postmenopausal women aged 50 to 79 years at enrollment, tested the most common formulations of hormone therapy prescribed at the time of study initiation: conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA) for women with an intact uterus and CEE alone for women with hysterectomy. The CEE plus MPA trial was stopped early (after 5.6 years) due to an increased risk of breast cancer and overall risks exceeding benefits 2 ; the CEE-alone trial was stopped after 7.2 years due to an increased risk of stroke. 3 Postintervention follow up has been ongoing. Health outcomes, including all-cause mortality from the 2 hormone therapy trials, have been reported, [2] [3] [4] [5] [6] [7] but previous publications have not focused on all-cause and causespecific mortality. Moreover, the current report includes extended follow-up and mortality surveillance of the entire randomized cohort using the National Death Index (NDI; 7489 deaths through December 31, 2014) . Hormone therapy has been shown to have a complex balance of benefits and risks with important effects on numerous outcomes-some of which differ between the 2 hormone therapy formulations. 2, 3, 6 Allcause mortality is a critically important summary measure representing the net effect of hormone therapy on serious and life-threatening health conditions. Thus, we examined total and cause-specific mortality during cumulative 18-year follow-up (intervention plus extended postintervention phases) of the 2 WHI hormone therapy trials, individually and pooled, with attention to potential differences by age.
Methods

Study Design
Details of the 2 WHI hormone therapy trial designs, adherence, and outcome adjudication procedures (including for mortality) have been previously published (trial protocol in Supplement 1). [1] [2] [3] 6 Briefly, 27 347 postmenopausal women ages 50 to 79 years were recruited from 1993 to 1998 at 40 US clinical centers; 16 608 women with a uterus were randomized to receive daily oral CEE (0.625 mg) plus MPA (2.5 mg, Prempro) or placebo and 10 739 women with hysterectomy were randomized to receive daily oral CEE (0.625 mg, Premarin) alone or placebo. The primary outcomes of both trials were incident coronary heart disease and invasive breast cancer. 1 Institutional review board approval was obtained at each center and all participants provided written informed consent. Race and ethnicity were self-reported. Postintervention follow-up included deaths through December 31, 2014 (median, 18 years cumulatively), with mortality ascertained by regular surveillance of the cohort through the NDI and by reports of next of kin or the postal service. NDI searches were conducted at 7 time points before 2015 for all participants who had unknown vital status. Some hazard ratios (HRs) may differ slightly from those previously reported due to more complete mortality ascertainment in the present report. After the trials were stopped, participants were unmasked to randomization assignment and fewer than 4% of women reported personal posttrial hormone therapy use.
Statistical Analysis
For each trial, cumulative analyses included all randomized participants according to their randomization assignment from time of randomization until death or December 31, 2014, the last date covered by the NDI linkage, based on the intentionto-treat principle. Mortality end points included all-cause mortality (primary analysis); cardiovascular disease (CVD) mortality (further subdivided into deaths from coronary heart disease, stroke, and other known CVD); cancer mortality (subdivided into deaths from breast, colorectal, and other known cancers); and other mortality (based on the other leading causes of death in women including Alzheimer disease or other dementia, chronic obstructive pulmonary disease [COPD], injuries and accidents, and other known causes). HRs were estimated using Cox proportional hazards models stratified by age and randomization status in the WHI Dietary Modification Trial. Preplanned analyses included presentation of cumulative and intervention-phase HRs and forest plots for each trial separately, as well as for the pooled trials unless the P value for heterogeneity between trials was less than .05 (eTables 1-3 in Supplement 2). HRs may exhibit time dependencies within or between phases as previously reported. 4, 5 Age subgroup analyses were preplanned for the major mortality end points. Interactions between randomization group and age stratum were based on a 1 degree-of-freedom test for linear trend; 10-year age groups (based on age at time of randomization) were assigned a continuous value (0,1, 2). HRs for younger vs older age groups were also directly compared as ratios.
Statistical tests were based on a 2-sided log-rank (score) test. Nominal (unadjusted) P values are provided and those of less than .05 were considered statistically significant. However, P values should be interpreted cautiously due to multiple comparisons. Sensitivity analyses were restricted to participants who took more than 80% of study pills (active or placebo) for at least 2 years or until death. All statistical analyses were conducted using SAS software version 9.3 (SAS Institute Inc) and R software version 2.15 (R Foundation for Statistical Computing, http://www.r-project.org/).
Results
Baseline Characteristics and Study Follow-up Periods
Baseline characteristics for the 2 randomization groups in each trial were well balanced on demographic and clinical risk factors (Table) . The CEE plus MPA trial ended in July 2002 (after a median of 5.6 years), 2, 6 and the CEE-alone trial ended in February 2004 (after a median of 7.2 years). 3, 6 The present report is based on mortality follow-up through December 31, 2014 (end of the last NDI search), and includes 7489 deaths (1088 occurred during the intervention phase and 6401 occurred postintervention; 4083 additional deaths since the last report). In addition to the intervention phases, the results reported in this study include median postintervention follow-up of 12.5 years and cumulative follow-up of 18 years for the CEE plus MPA trial and a median postintervention follow-up of 10.8 years and cumulative follow-up of 18 years for the CEE-alone trial ( Figure 1) . Mortality is more than 98% complete, based on NDI evaluation. (Figure 2 ; eTable 1 in Supplement 2).
Intervention and Postintervention Phases
Neither treatment was significantly associated with CVD mortality during the intervention phase (eFigure and eTable 2 in Supplement 2). Compared with placebo, women in the CEE plus MPA group had an HR of 1.08 (95% CI, 0.78-1.48; P = .65) and women in the CEE-alone group had an HR of 1.01 (95% CI, 0.78-1.31; P = .95). Similarly, the HRs for deaths due to coronary heart disease, stroke, and other known CVD causes were not significantly increased or decreased in either trial during the intervention (eFigure and eTable 2 in Supplement 2) or postintervention phases (eTable 3 in Supplement 2).
Age-Stratified Analyses
No statistically significant trends for CVD with age were observed in either trial during any study phase ( Figure 3 and Figure 4 ; eTables 1-3 in Supplement 2).
Cancer Mortality
Cumulative (95% CI, 0.97-2.15; P = .07) for CEE plus MPA and 0.55 (95% CI, 0.33-0.92; P = .02) for CEE alone; due to heterogeneity between risk estimates (P value for heterogeneity = 0.003), we did not pool these analyses. HRs for deaths from colorectal cancer or other cancers were not statistically significant in either trial ( Figure 2 ). 
Intervention and Postintervention Phases
Neither intervention was significantly associated with total cancer mortality (eFigure, eTable 2, and eTable 3 in Supplement 2). During the intervention phase, women receiving CEE plus MPA had an HR of 1.10 (95% CI, 0.86-1.42; P = .44) and those receiving CEE alone had an HR of 0.96 (95% CI, 0.75-1.22; P = .72), compared with placebo. For breast cancer mortality, the HR was 1.08 (95% CI, 0.29-4.03; P = .91) for CEE plus MPA and the HR was 0.45 (95% CI, 0.14-1.46; P = .17) for CEE alone, but number of deaths was small; differences became more pronounced during the postintervention phase (eTable 3 in Supplement 2). The interventions were not significantly associated with colorectal cancer or other cancer mortality (eFigure, eTable 2, and eTable 3 in Supplement 2).
Age-Stratified Analyses
In the pooled cohort, the HR for total cancer mortality during the intervention phase was 0.74 (95% CI, 0.48-1.14) for women aged 50 to 59 years and ranged from 1.00 (95% CI, 0.77-1.28) for women aged 60 to 69 years to 1.24 (95% CI, 0.93-1.66) for women aged 70 to 79 years (P value for trend by age = 0.05; Figure 3 ). These age trends persisted over cumulative follow-up (P value for trend by age = 0.05 for the pooled cohort Figure 4 ; eTable 1 in Supplement 2). Over cumulative follow-up, HRs for colorectal cancer were elevated for the women aged 70 to 79 years in the CEE-alone trial (HR = 2.13 [95% CI, 1.10-4.12]; P value for trend by age = 0.03; eTable 1 in Supplement 2). (Figure 2 ; eTable 1 in Supplement 2). HRs for deaths from COPD, accidents or injuries, and other causes were not significantly increased or decreased during cumulative follow-up in either trial (Figure 2 ).
Intervention and Postintervention Phases
During the intervention phase, the HR for other (non-CVD, noncancer) causes of mortality was 0.59 (95% CI, 0.39-0.90; P = .01) for CEE plus MPA vs placebo but did not differ by treatment group in the CEE-alone trial. Regarding specific causes of death, there were fewer deaths from COPD during the CEE plus MPA intervention (eFigure in Supplement 2), but the number of events was small. 
Age-Stratified Analyses
HRs for other (non-CVD, noncancer) mortality during the intervention phase were similar across age groups for CEE plus MPA but lower for younger women than for older women in the CEE trial (P value for trend by age = 0.002) ( Figure 3 ; eTable 2 in Supplement 2). However, numbers of events of individual outcomes (COPD, dementia, injuries or accidents, other) were too small to assess cause-specific differences by age during the intervention. During cumulative follow-up, lower risks of non-CVD, noncancer mortality persisted among women aged 50 to 59 years in the CEE-alone trial (HR = 0.63; 95% CI, 0.45-0.89), although the trend for age was no longer significant (P value for trend = 0.22) (Figure 4 ). There were fewer deaths from COPD among women aged 50 to 59 years in the CEE trial (eTable 1 in Supplement 2), but the number of events was small.
Additional Analyses
In additional sensitivity analyses censoring participants who took less than 80% of study pills (active or placebo) during the first 2 years, results were generally similar to intentionto-treat results, but statistical power was reduced. For cumulative follow-up, the HR for all-cause mortality was 1.03 (95% CI, 0.95-1.11) for the CEE plus MPA trial and 0.94 (95% CI, 0.86-1.03) for CEE alone. The pattern suggestive of lower mortality risks for younger women when compared with older women during the intervention phase persisted in these analyses (P value for trend by age = 0.05 in pooled analyses), but age trends were not statistically significant during cumulative follow up. In analyses of all-cause and cause-specific mortality with stratification by time since menopause, results were generally similar to the agestratified analyses, but statistical power was lower due to missing age at menopause for many participants. In addition, sensitivity analyses adjusted for time-varying differences in initiation of statins between treatment group, 9 had no appreciable effect on the results.
Discussion
During cumulative 18-year follow-up among 27 347 postmenopausal women in the WHI hormone therapy trials, CEE plus MPA and CEE alone were not associated with increased or decreased risk of all-cause, cardiovascular, or total cancer mortality. Based on 7489 cumulative deaths over 18 years (1088 deaths during the intervention phase and 6401 deaths during postintervention follow-up [ Figure 1 ]; >98% ascertainment of mortality), HRs for all-cause mortality in the hormone therapy group vs the placebo group were 0.99 (95% CI, 0.94-1.03; P = .60) in the overall pooled cohort, 1.02 (95% CI, 0.96-1.08; P = .51) with CEE plus MPA, and 0.94 (95% CI, 0.88-1.01; P = .11) with CEE alone (Table) . HRs for all-cause mortality also did not differ between the hormone therapy and placebo groups during the intervention phases of the trials. When examined by 10-year age group (based on age at randomization) comparing women aged 50 to 59 years to those aged 70 to 79 years, the ratios of nominal HRs for all-cause mortality in the pooled cohort were 0.61 (95% CI, 0.43-0.87) during the intervention phase and 0.87 (95% CI, 0.76-1.00) during cumulative 18-year follow-up (eTable 4 in Supplement 2), without significant heterogeneity between trials. The trend by age group was statistically significant during the intervention phase but not during the cumulative follow-up period.
Results for cause-specific mortality should be interpreted cautiously due to multiple comparisons. Although younger women (aged 50-59 years) tended to have lower HRs than older women for mortality due to CVD, cancer, and other (non-CVD, noncancer) causes during the intervention phases of the 2 trials, only the latter outcome in the CEE-alone trial showed a statistically significant trend with age (P value for trend by age = .002), partially influenced by adverse effects of CEE in women aged 70 to 79 years. During cumulative followup, trends in cause-specific mortality across age groups were not statistically significantly different. For non-CVD, noncancer mortality, the significantly reduced risk among younger women in the pooled trials during the intervention phase (HR, 0.52 [95% CI, 0.28-0.97]; P value for trend by age = .01; eTable 2 in Supplement 2) appeared attributable to small reductions in several outcomes rather than a marked reduction in a single outcome; a risk reduction persisted only for CEE during cumulative follow-up. The observed reduction in deaths from Alzheimer disease or other dementia in the CEE trial and pooled cohort requires particular caution in view of findings of adverse effects of these interventions on cognitive function and incident dementia in the WHI Memory Study. 10, 11 Although rates of dementia mortality in WHI are well aligned with agespecific national statistics, 12 deaths from dementia can be underreported, and competing risks from other causes of death or confounding cannot be excluded. It is unknown whether favorable effects of hormone therapy on insulin resistance and diabetes 13,14 -major determinants of cognitive decline- 15, 16 contributed to these findings. In view of the complex balance of benefits and risks of hormone therapy, the all-cause mortality outcome provides an important summary measure, representing the net effect of hormone therapy use for 5 to 7 years on life-threatening outcomes. Previous WHI reports have focused on incident diagnoses such as coronary heart disease, stroke, breast cancer, hip fracture, and other major outcomes-all of which are serious but predominantly nonfatal and led to fewer than half of the deaths in the cohort. The current analyses include a large number of deaths during 18 years of follow-up (4354 deaths in the CEE plus MPA trial and 3135 in the CEE trial). Given the hormone therapy-related health risks identified in the CEE plus MPA trial 2,6,10 and the CEE-only trial 3, 6 , it is noteworthy that no elevations in all-cause mortality were found during either the intervention or cumulative follow-up phases of these trials. Although these findings lend support to practice guidelines endorsing use of hormone therapy for recently menopausal women with moderate-to-severe symptoms, in the absence of contraindications, [17] [18] [19] the attenuation of age differences with longer follow-up and potential health risks of treatment 6, 20, 21 would not support use of hormone therapy for reducing chronic disease or mortality. Moreover, it is unclear whether benefits would outweigh risks with longer duration of treatment. In clinical decision making, these considerations must be weighed against the evidence linking untreated vasomotor symptoms in midlife women to impaired health and quality of life, disrupted sleep, reduced work productivity, and increased health care expenditures. 17, 22, 23 No other randomized clinical trial of hormone therapy, to our knowledge, has been large enough to assess a potential modifying effect of age on all-cause mortality, and most previous trials of chronic disease outcomes have focused on older women. 17, 24 Observational studies, which include primarily women who initiate hormone therapy in early menopause, have generally demonstrated lower mortality among women using hormone therapy compared with nonusers, [25] [26] [27] [28] although few studies have distinguished between estrogen alone and combination estrogen plus progestin. HRs in most large cohort studies have ranged from 0.40 to 0.80, [25] [26] [27] [28] but such studies may be susceptible to several potential sources of confounding. 17, 29 Regarding cause-specific mortality, the most marked risk reductions reported in observational studies have been for coronary or CVD deaths. The potential influence of age on the relation between hormone therapy and vascular disease has received considerable attention, including divergent effects of hormone therapy on atherosclerotic lesions in early vs late menopause. [30] [31] [32] [33] Total cancer mortality did not differ significantly between intervention and placebo groups in either trial despite the increased incidence of breast cancer with CEE plus MPA 34 and concerns about an increased risk of hormone-sensitive cancers with both regimens. 29 Hormone therapy has a complex relationship with cancer. Although a significant reduction in breast cancer was seen with CEE, 35 ,36 a significant increase in breast cancer incidence with CEE plus MPA has been documented. 6, 37 Divergent findings for CEE alone and CEE plus MPA for breast cancer point to an adverse effect of progestin on the breast epithelium, 38 but progestins have been linked to favorable effects on the endometrium and a decreased risk of endometrial cancer became apparent with long-term follow-up of the CEE plus MPA trial. 6, 39 Moreover, these regimens did not appear to alter mortality outcomes for other cancer sites, including lung cancer, and had no significant effect on total cancer incidence. 6 Several limitations of this study warrant consideration. Only 1 dose, formulation, and route of administration in each trial was assessed; thus, results are not necessarily generalizable to other hormone preparations. The greater than 98% follow-up through the NDI obviates many of the concerns of previous WHI reports covering postintervention follow-up; virtually all cohort deaths are captured in these analyses due to the NDI searches. Nonetheless, specificity of cause of death may vary across outcomes. Finally, the nominal P values presented here should be interpreted cautiously, as multiple outcomes and subgroups were examined. Thus, cause-specific mortality analyses should be considered exploratory.
Conclusions
Among postmenopausal women in WHI, hormone therapy with CEE plus MPA for a median of 5.6 years or CEE for a median of 7.2 years was not associated with risk of all-cause, cardiovascular, or total cancer mortality during a cumulative follow-up of 18 years.
